About this Journal Submit a Manuscript Table of Contents
Prostate Cancer
Volume 2012 (2012), Article ID 814724, 11 pages
http://dx.doi.org/10.1155/2012/814724
Research Article

Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 Trial

1School of Medicine and Public Health, The University of Newcastle, University Drive, Callaghan, NSW 2308, Australia
2Department of Radiation Oncology, Calvary Mater Newcastle, Locked Bag 7, Hunter Region Mail Centre, NSW 2310, Australia
3Department of Radiation Oncology, Wellington Cancer Centre, Riddiford Street, Newtown, Wellington 6021, New Zealand
4Department of Radiation Oncology, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, Perth, WA 6009, Australia
5Department of Radiation Oncology, Auckland Hospital, 2 Park Road, Grafton, Auckland 1023, New Zealand
6Department of Radiation Oncology, St George's Cancer Care Centre, 131 Leinster Road, Strowan, Christchurch 8014, New Zealand
7Department of Radiation Oncology, Westmead Hospital, Corner Hawkesbury Road and Darcy Road, Westmead, NSW 2145, Australia
8Department of Radiation Oncology, Dunedin Hospital, 201 Great King Street, Dunedin 9054, New Zealand
9Department of Radiation Oncology, Premion, Inland Drive, Tugun, QLD 4224, Australia
10Department of Radiation Oncology, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, VIC 3002, Australia

Received 20 July 2012; Revised 3 October 2012; Accepted 12 November 2012

Academic Editor: Harold A. Frazier

Copyright © 2012 Allison Steigler et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. H. Klotz, “PSA recurrence: definitions, PSA kinetics, and identifying patients at risk,” The Canadian Journal of Urology, vol. 13, pp. 43–47, 2006. View at Scopus
  2. J. W. Moul, “Prostate specific antigen only progression of prostate cancer,” The Journal of Urology, vol. 163, no. 6, pp. 1632–1642, 2000. View at Scopus
  3. M. N. Simmons, A. J. Stephenson, and E. A. Klein, “Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy,” European Urology, vol. 51, no. 5, pp. 1175–1184, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. R. de Wit, “New hope for patients with metastatic hormone-refractory prostate cancer,” European Urology Supplements, vol. 5, no. 15, pp. 817–823, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. H. M. Sandler, R. L. Dunn, P. W. McLaughlin, J. A. Hayman, M. A. Sullivan, and J. M. G. Taylor, “Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy,” International Journal of Radiation Oncology, Biology and Physics, vol. 48, no. 3, pp. 629–633, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. A. V. D'Amico, K. Cote, M. Loffredo, A. A. Renshaw, and D. Schultz, “Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer,” Journal of Clinical Oncology, vol. 20, no. 23, pp. 4567–4573, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. J. W. Moul, “Variables in predicting survival based on treating “PSA-Only” relapse,” Urologic Oncology, vol. 21, no. 4, pp. 292–304, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. O. T. Okotie, W. J. Aronson, J. A. Wieder et al., “Predictors of metastatic disease in men with biochemical failure following radical prostatectomy,” The Journal of Urology, vol. 171, no. 6, pp. 2260–2264, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. A. J. Stephenson, P. T. Scardino, M. W. Kattan, et al., “Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy,” Journal of Clinical Oncology, vol. 25, no. 15, pp. 2035–2041, 2007.
  10. S. J. Freedland, E. B. Humphreys, L. A. Mangold et al., “Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy,” Journal of the American Medical Association, vol. 294, no. 4, pp. 433–439, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. Z. A. Dotan, F. J. Bianco Jr., F. Rabbani et al., “Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy,” Journal of Clinical Oncology, vol. 23, no. 9, pp. 1962–1968, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. S. F. Slovin, A. S. Wilton, G. Heller, and H. I. Scher, “Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy,” Clinical Cancer Research, vol. 11, no. 24, pp. 8869–8873, 2006. View at Publisher · View at Google Scholar
  13. P. Zhou, M. H. Chen, D. McLeod, P. R. Carroll, J. W. Moul, and A. V. D'Amico, “Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy,” Journal of Clinical Oncology, vol. 23, no. 28, pp. 6992–6998, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. M. K. Tollefson, J. M. Slezak, B. C. Leibovich, H. Zincke, and M. L. Blute, “Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy,” Mayo Clinic Proceedings, vol. 82, no. 4, pp. 422–427, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. M. K. Buyyounouski, A. L. Hanlon, E. M. Horwitz, and A. Pollack, “Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy,” International Journal of Radiation Oncology, Biology and Physics, vol. 70, no. 1, pp. 59–66, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. J. W. Denham, A. Steigler, C. Wilcox et al., “Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival?” Cancer, vol. 115, no. 19, pp. 4477–4487, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. J. W. Denham, A. Steigler, C. Wilcox et al., “Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial,” The Lancet Oncology, vol. 9, no. 11, pp. 1058–1068, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. A. V. D'Amico, J. W. Moul, P. R. Carroll, L. Sun, D. Lubeck, and M. H. Chen, “Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy,” Journal of the National Cancer Institute, vol. 95, no. 18, pp. 1376–1383, 2003. View at Scopus
  19. J. A. Eastham, “Prostate-specific antigen doubling time as a prognostic marker in prostate cancer,” Nature Clinical Practice Urology, vol. 2, no. 10, pp. 482–491, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Maffezzini, A. Bossi, and L. Collette, “Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer,” European Urology, vol. 51, no. 3, pp. 605–613, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. G. E. Hanks, A. L. Hanlon, W. R. Lee, A. Slivjak, and T. E. Schultheiss, “Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior,” International Journal of Radiation Oncology, Biology and Physics, vol. 34, no. 3, pp. 549–553, 1996. View at Publisher · View at Google Scholar · View at Scopus
  22. J. F. Ward, M. L. Blute, J. Slezak, E. J. Bergstralh, and H. Zincke, “The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy,” The Journal of Urology, vol. 170, no. 5, pp. 1872–1876, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. P. C. Albertsen, J. A. Hanley, D. F. Penson, and J. Fine, “Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation,” The Journal of Urology, vol. 171, no. 6, pp. 2221–2225, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. C. R. Pound, A. W. Partin, M. A. Eisenberger, D. W. Chan, J. D. Pearson, and P. C. Walsh, “Natural history of progression after PSA elevation following radical prostatectomy,” Journal of the American Medical Association, vol. 281, no. 17, pp. 1591–1597, 1999. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Pollack, A. L. Hanlon, B. Movsas, G. E. Hanks, R. Uzzo, and E. M. Horwitz, “Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy,” International Journal of Radiation Oncology, Biology and Physics, vol. 57, no. 1, pp. 19–23, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. M. J. Zelefsky, L. Ben-Porat, H. I. Scher et al., “Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer,” Journal of Clinical Oncology, vol. 23, no. 4, pp. 826–831, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Alcántara, A. Hanlon, M. K. Buyyounouski, E. M. Horwitz, and A. Pollack, “Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastatis and death,” Cancer, vol. 109, no. 1, pp. 41–47, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. S. J. Freedland, E. B. Humphreys, L. A. Mangold, M. Eisenberger, and A. W. Partin, “Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality,” The Journal of Urology, vol. 176, no. 4, pp. 1404–1408, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. G. K. Zagars and A. Pollack, “Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer,” Radiotherapy and Oncology, vol. 44, no. 3, pp. 213–221, 1997. View at Publisher · View at Google Scholar · View at Scopus
  30. G. E. Hanks, A. D'Amico, B. E. Epstein, and T. E. Schultheiss, “Prostatic-specific antigen doubling times in patients with prostate cancer: a potentially useful reflection of tumor doubling time,” International Journal of Radiation Oncology, Biology and Physics, vol. 27, no. 1, pp. 125–127, 1993. View at Scopus
  31. C. I. Sartor, M. H. Strawderman, X. H. Lin, K. E. Kish, P. W. McLaughlin, and H. M. Sandler, “Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy,” International Journal of Radiation Oncology, Biology and Physics, vol. 38, no. 5, pp. 941–947, 1997. View at Publisher · View at Google Scholar · View at Scopus
  32. J. W. Denham, A. Steigler, D. S. Lamb et al., “Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial,” The Lancet Oncology, vol. 6, no. 11, pp. 841–850, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Roach III, G. Hanks, H. Thames Jr., et al., “Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference,” International Journal of Radiation Oncology, Biology and Physics, vol. 65, no. 4, pp. 965–974, 2006. View at Publisher · View at Google Scholar
  34. J. W. Denham, A. Steigler, D. S. Lamb et al., “Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial,” The Lancet Oncology, vol. 12, no. 5, pp. 451–459, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. J. P. Fine and R. J. Gray, “A proportional hazards model for the subdistribution of a competing risk,” Journal of the American Statistical Association, vol. 94, no. 446, pp. 496–509, 1999. View at Scopus
  36. F. E. Harrell Jr., K. L. Lee, and D. B. Mark, “Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors,” Statistics in Medicine, vol. 15, no. 4, pp. 361–387, 1996.
  37. A. V. D'Amico, R. Whittington, S. B. Malkowicz, et al., “Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer,” The Journal of the American Medical Association, vol. 280, no. 11, pp. 969–974, 1998. View at Publisher · View at Google Scholar
  38. TOAD Trial: Timing of androgen deprivation therapy in prostate cancer patients with a rising PSA, TROG 03-06, NCT00110162, 2005.
  39. ELAAT Trial, “Early vs late androgen ablation therapy for recurrent prostate cancer post-radiotherapy,” 2007, http://www.clinicaltrials.gov/ct/show/NCT00439751.
  40. D. P. Dearnaley, M. R. Sydes, J. D. Graham et al., “Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial,” The Lancet Oncology, vol. 8, no. 6, pp. 475–487, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. J. W. Denham, M. Kumar, P. S. Gleeson et al., “Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer,” International Journal of Radiation Oncology, Biology and Physics, vol. 74, no. 2, pp. 404–411, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. TROG 03.04 RADAR Trial—Randomised Androgen Deprivation and Radiotherapy, 2005, http://clinicaltrials.gov/ct/show/NCT00193856?order=5.